[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615936":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":31,"responsibleParty":43,"collaborators":30,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":30,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":30,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":68,"whyStopped":30,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with Type 2 Diabetes","EXPERIMENTAL","Participants will receive tirzepatide subcutaneously (SC)",[13],"Drug: Tirzepatide",{"label":15,"type":10,"description":16,"interventionNames":17},"Participants with Overweight or Obesity Without Type 2 Diabetes","Participants will receive tirzepatide SC",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Tirzepatide","Administered SC",[15,9],[25],"LY3298176",[27],{"name":28,"affiliation":5,"role":29},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",null,[32],{"facility":33,"status":30,"city":34,"state":30,"zip":35,"country":34,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":30},"Lilly Centre for Clinical Pharmacology","Singapore","138623","SG",{"type":38,"coordinates":39},"Point",[40,41],103.85007,1.28967,{"lat":41,"lon":40},{"type":44,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100615936","phase-1-a-study-to-evaluate-the-effect-of-fasting-duration-and-tirzepatide-withholding-on-the-amount-of-food-and-fluid-in-the-stomach-in-participants-with-type-2-diabetes-mellitus-and-participants-with-overweight-or-obesity-without-type-2-diabetes-mellitus-100615936",false,"NCT07299084","A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus","A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Meet one of the following criteria:\n\n  * Have type 2 diabetes\n  * Have obesity\n  * Have overweight with at least one health issue related to weight but without type 2 diabetes\n\nExclusion Criteria:\n\n* Have a condition that affects how their stomach empties\n* Have had weight loss surgery\n* Have type 1 diabetes\n* Have any major medical conditions or histories that could interfere with the study","ALL","18 Years","70 Years",{"count":56,"type":57},40,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.",[63,64,65],"Diabetes Mellitus, Type 2","Overweight","Obesity",[67],"Point of Care Ultrasound (POCUS)","ACTIVE_NOT_RECRUITING","2026-05-18",{"date":71,"type":72},"2026-05-19","ACTUAL",{"date":74,"type":72},"2026-01-14",{"date":76,"type":57},"2026-11",{"name":5,"class":6},1]